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Dominant Mutations in KBTBD13, a Member of the
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We identified amember of the BTB/Kelch protein family that is mutated in nemalinemyopathy type 6 (NEM6), an autosomal-dominant
neuromuscular disorder characterized by the presence of nemaline rods and core lesions in the skeletal myofibers. Analysis of affected
families allowed narrowing of the candidate region on chromosome 15q22.31, and mutation screening led to the identification of
a previously uncharacterized gene, KBTBD13, coding for a hypothetical protein and containing missense mutations that perfectly cose-
gregate with nemaline myopathy in the studied families. KBTBD13 contains a BTB/POZ domain and five Kelch repeats and is expressed
primarily in skeletal and cardiac muscle. The identified disease-associated mutations, C.742C>A (p.Arg248Ser), c.1170G>C
(p.Lys390Asn), and c.1222C>T (p.Arg408Cys), located in conserved domains of Kelch repeats, are predicted to disrupt the molecule’s
beta-propeller blades. Previously identified BTB/POZ/Kelch-domain-containing proteins have been implicated in a broad variety of bio-
logical processes, including cytoskeleton modulation, regulation of gene transcription, ubiquitination, and myofibril assembly. The
functional role of KBTBD13 in skeletal muscle and the pathogenesis of NEM6 are subjects for further studies.Nemaline myopathy (NEM) is the most common nondy-
strophic congenital myopathy that affects mainly infants
and children. Thepresence of thread- or rod-like (nemaline)
bodies in affectedmuscle is the histological hallmark of this
myopathy. A variety of distinct clinical types of NEM are
recognized and are based on the age at disease onset and
the severity of muscle weakness, ranging from a severe,
neonatal, and often fatal disease to milder, nonprogressive
or slowly progressive disease presenting in infancy, child-
hood, or adulthood.1,2 The major symptoms are muscle
weakness with hypotrophy of diffuse distribution or
limited to the face, neck, and proximal limbs but in some
patients extending to respiratory muscles. The pattern of
inheritance is also variable; autosomal-recessive and auto-
somal-dominant forms are knownand sporadic cases are re-
ported.3,4 Mutations causing phenotypically distinct NEM
variants have been identified in a-actin (ACTA1 [MIM
161800]), a-slow tropomyosin and b-tropomyosin (TPM3
[MIM 609284] and TPM2 [MIM 60928]), troponin T
(TNNT1 [MIM 605355]), nebulin (NEB [MIM 256030]),
and cofilin2 (CFL2 [MIM 610687]). Each known NEM
gene encodes components of skeletal muscle sarcomeric
thin filaments or regulators of their assembly.3–5 Despite
recent progress, the molecular mechanisms remain
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842 The American Journal of Human Genetics 87, 842–847, DecembWe previously mapped autosomal-dominant NEM in
two pedigrees, Dutch and Australian Dutch, to a locus on
chromosome 15q21-q23, with a combined LOD score of
10.65 at marker D15S993.6 We later identified two addi-
tional families, Spanish7 and Australian-Belgian, featuring
a similar phenotype and genetically linked to the same
chromosomal locus. This type of nemaline myopathy
was named NEM type 6 (NEM6 [MIM 609273]). The clin-
ical phenotype of the 42 studied patients includes poor
exercise tolerance, characteristic slowness of movements,
gait abnormality, and the development of slowly progres-
sive muscle weakness of the neck and proximal limb
muscles beginning in childhood (Table 1). The slowness
of movements observed in NEM6 patients is not a charac-
teristic feature in other congenital myopathies.7,8 The
NEM6 patients were unable to run and to correct them-
selves from falling over. This slowness was constant and
was not influenced by the environment. The slowness in
NEM6 was correlated to a slower torque generation and
a lower rate of relaxation.7 Muscle biopsies demonstrate
strikingly similar cross-family images. These include
numerous nemaline rods that form confluent inclusions
(Figure 1A) near the Z-disks associated with sarcomere
disorganization, but some rods are not colocalized with
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Table 1. Clinical Manifestations in NEM6 Patients
Family Australian Dutch Dutch Spanish Australian Belgian
Number of studied
patients
10 24 4 4
Age at onset childhood childhood childhood childhood
First symptom unable to run
or jump;
difficulties on
stairs
unable to run
or jump;
difficulties on
stairs
unable to run
or jump;
difficulties on
stairs
unable to skip
or jump
Progression slow slow, disabling
after age 50
yrs
slow, disabling
after age 30
yrs
variable,
Gower’s maneuver as
early as 19 years
Distribution ofmuscle
weakness
neck, proximal,
distal in one
patient
neck and proximal proximal and
distal;
neck in two
patients
proximal greater
than distal;
neck weakness
in some
Respiratory
insufficiency
no no no no
Muscle atrophy none diffuse in the
most severely
affected patient
deltoids,
forearms
none
Other symptoms movement
slowness in
one patient
movement
slowness
movement
slowness
movement
slowness in
one patient
EMG profile myogenic myogenic myogenic myogenic
Creatine kinase level normal normal normal normal
Cardiac abnormalities none identified none identified none identified none identifiedoxidative enzyme activity represent an associated feature
of the NEM6 subtype (Figure 1C). A combination of nema-
line rods and core lesions has also been seen in some
patients with mutations in ryanodine receptor (RYR1
[MIM 180901]).9,10 However, it is noteworthy that the
core lesions observed in NEM6 differ from the classicalThe Americansharply demarcated cores observed in central core or
core-rod disease associated with mutations in RYR1.7
Another unifying feature of the NEM6 subtype is the
predominance and hypertrophy of type 1 (slowly twitch-
ing) fibers versus atrophic type 2 (fast) fibers (Figure 1D).
This pattern is characteristic of the NEM6 subtype and isFigure 1. Histochemical, Ultrastructural, and
Immunohistochemical Findings in a Muscle
Biopsy Sample from the Right Biceps Brachii
Muscle Biopsy of the Spanish Family Index
Patient
(A) Clusters of nemaline rods on modified tri-
chrome staining forming confluent inclusion in
some areas under the sarcolemma and centrally
within the cytoplasm (scale bar represents
50 mm).
(B) Electron micrograph showing multiple nema-
line rods located under the sarcolemma and near
Z-disks (scale bar represents 2 mm).Muscle sample
fixed in 2% glutaraldehyde, postfixed with 1%
osmium tetroxide, was embedded in araldite.
Ultrathin sections were stained with uranyl
acetate and lead citrate andwere viewed and pho-
tographed with a JEOL 1011electron microscope.
(C) Cores devoid of oxidative enzyme activity
appear on NADH reaction (scale bar represents
50 mm).
(D) Double-labeling immunohistochemistry for
slow (pale) and fast (dark) myosin demonstrating
type 1 fiber predominance and hypertrophy
versus type 2 fiber atrophy (scale bar represents
50 mm).
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Figure 2. KBTBD13Mutations in NEM6 Families
(A) The NEM6 locus is a 6.7 Mb interval delimited
by markers D15S155 and D15S125, which physi-
cally map between the 58.1 Mb and 68.4 Mb
chromosomal positions. The region contains 28
genes expressed in striated muscle.
(B) KBTBD13 mutations identified in NEM6
patients are located within the highly conserved
second and fifth Kelch repeats.
(C) Evolutionary conservation of KBTBD13
domains. The mutated residues are shown in
bold.rarely seen in other subtypes. Rods and cores were jointly
present in biopsy samples representing each studied
family, affecting 10% to 95% of fibers when measured,
and type I fiber predominance and hypertrophy were
seen in each case but one (Table S1 available online).
Genetic studies were approved by the institutional
review boards of all collaborating institutions and were
performed in accordance with the Declaration of Hel-
sinki, and all subjects gave written informed consent
prior to participation. We reanalyzed the NEM6 candidate
region on the basis of haplotype analysis in three pedi-
grees and determined that the associated gene is located
in a 6.7 Mb region flanked by markers D15S155 and
D15S125 on chromosome 15q22.31 (Figure 2A). The
region contains more than 70 annotated protein-coding
genes (NCBI build 37.1). The most attractive candidate
within the NEM6 interval was a-fast tropomyosin
(TPM1 [MIM 191010]), which encodes a thin filament
protein expressed in type 2 (fast) skeletal muscle fibers
and cardiomyocytes. TPM1 mutations are known to cause
familial hypertrophic cardiomyopathy type 311 and
dilated cardiomyopathy,12 and mutations in other tropo-
myosins cause nemaline myopathy.13 However, extensive
analysis of the coding exons of TPM1 and its regulatory
regions failed to identify mutations in the Dutch, Austra-
lian Dutch, or Spanish patients. To rule out the possibility
of genomic rearrangements within the candidate region,
we surveyed the genome of three affected individuals,
using Affimetrix 6.0 SNP chips according to the manufac-
turer’s guidelines. This array contains probes specific for
the detection of both SNPs and copy-number variants
(CNVs). CNVs were determined with the Partek Geno-
mics Suite (version 6.4, build 6.09.0310) and analyzed
with the copy number analysis workflow. An 11.1 kb
intragenic deletion in a patient from the Australian844 The American Journal of Human Genetics 87, 842–847, December 10, 2010Dutch family was identified within the
candidate region (data not shown), but
this deletion was absent in the patient’s
affected mother and the index case of the
Spanish family, thus excluding disease-
specific CNVs.
We then performed mutation screening
of 28 genes within the region (Figure 2A).
The genes were selected on the basis of thefunction of encoded proteins and expression in striated
muscles. The exons with intronic flanking regions or the
cDNA were analyzed for sequence variants in two patients
from the Australian Dutch and Spanish families and in two
controls. Sequence analysis of candidate genes resulted in
the identification of a number of synonymous and
nonsynonymous SNPs (Table S2). The nonsynonymous
SNPs were then tested in other patients from the same
and additional NEM6 families. Potentially disease-causing
c.1170G>C (p.Lys390Asn) and c.1222C>T (p.Arg408Cys)
mutations were found in a nonannotated and uncharacter-
ized LOC390594 gene that was subsequently designated as
‘‘Kelch-repeat and BTB (POZ) domain containing 13’’
(KBTBD13 [accession no. NM_001101362.2]) (Figure 2B).
The c.1170G>C (p.Lys390Asn) mutation was identified
in each patient of the Spanish family, and the
c.1222C>T (p.Arg408Cys) mutation perfectly segregated
with the disease in the original Dutch, Australian Dutch,
and Australian Belgian pedigrees (Figure S1). Analysis of
haplotypes based on seven microsatellite markers covering
a 1.7 Mb region around KBTBD13 showed allele sharing
between the latter three families (Figure S2), suggesting
that a founder effect for the c.1222C>T mutation may
exist in the Low Countries of The Netherlands and
Belgium. KBTBD13 was subsequently screened in 14
probands with pathologically diagnosed rod-core disease.
A c.742C>A (p.Arg248Ser) variant was found in a single
isolated case from Victoria, Australia (Figure 2B). All three
KBTBD13 mutations occurred at amino acid positions
conserved through evolution and alter positively charged
amino acids (Figure 2C). None of the KBTBD13mutations
was found in control individuals. The c.1170G>C
(p.Lys390Asn) and c.1222C>T (p.Arg408Cys) mutations
were absent in 80 Spanish, 52 Dutch, and 84 healthy
Americans of European descent. Although the parents
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Figure 3. Tissue-Specific Expression of the Mouse KBTBD13
Tissue source is indicated on top of loaded RT-PCR products.
GAPDH was used as internal control for normalization of cDNA
quantity. The sizes of cDNA fragments are 249 bp for KBTBD13
and 101 bp for GAPDH.and siblings of the patient with the p.Arg248Ser substitu-
tion were not available for further study, we consider this
variant as a candidate mutation because it was absent
among 148 Australian and 52 Dutch controls.
KBTBD13 is located between nucleotides 65369154 and
65370530 in the NM_001101362.2 sequence of chromo-
some 15q22.31. The first in-frame ATG of KBTBD13 is
flanked by a Kozak sequence, and the gene has a single
exon. The predicted open reading frame comprises 1374
nucleotides encoding a protein, KBTBD13, of 458 amino
acids with a molecular mass of 49 kDa (NP_001094832).
Highly conserved proteins of a similar size are predicted
in vertebrates that share from 51% to 99% identity with
human KBTBD13 (data not shown). A single transcript of
3.5 kb was detected in an RNA blot of human skeletal
muscle poly Aþ RNA (Figure S3), and a mouse KBTBD13The Americanortholog (NM_028974; NP_083250) was identified in skel-
etal and cardiac muscles and lung by RT-PCR testing of
multiple tissues (Figure 3). Although KBTBD13 is expressed
in the heart, to date no cardiac abnormalities have been
identified in affected individuals (Table 1). A focused study
of cardiac involvement in NEM6 patients has been
performed in two patients of the Spanish family. Electro-
cardiography, 24 hr Holter monitoring, and echocardiog-
raphy have not shown any notable alterations.
For determination of subcellular localization, the wild-
type human KBTBD13 cDNA was generated by RT-PCR
using skeletal muscle RNA. The c.1222C>T (p.Arg408Cys)
mutation was introduced into a wild-type clone through
site-directed mutagenesis (Stratagene). The full-length
KBTBD13 transcript was cloned into the pCMV6-AC-
MycDDK expression vector (OriGene) and transfected
into differentiating C2C12 myotubes and embryonic
mouse cardiomyocytes prepared from CD-1 mouse
embryos as described previously.14 Both wild-type and
mutant KBTBD13 showed a punctate distribution
throughout the cytoplasm in both types of cells. In the
cardiomyocytes (Figure 4), KBTBD13 does not colocalize
with a-actinin, the major protein component of the
Z-disks and the nemaline bodies. This may indicate that
the disease mechanisms in NEM6 are fundamentally
different from other NEMs. Expression of mutant
KBTBD13 showed no gross difference compared to the
wild-type KBTBD13 (Figure 4). It is perhaps not surprising,
given that NEM6 is a mild, very slowly progressive
disorder. However, these experiments are limited to subcel-
lular localization of the protein and do not reveal the
pathogenic consequences of mutations. Antibody staining
of the endogenous protein is a better tool for the analysis
of localization and mutation-specific changes in human
NEM6 biopsies and cell models, but no antibodies against
KBTBD13 are currently available.Figure 4. Localization of KBTBD13 Tagged
with Myc-Flag in Embryonic Mouse Cardiomyo-
cytes
Top images: wild-type KBTBD13; bottom images:
p.Arg408Cys mutant KBTBD13. KBTBD13 is
stained in red and a-actinin in green; the nucleus
is labeled in blue with DAPI. Inset: higher magni-
fication of boxed areas shows no visible colocali-
zation of the wild-type or mutant KBTBD13
(arrowheads) with a-actinin in striated premyofi-
brils (arrows). Scale bar represents 10 mm.
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KBTBD13 is predicted to contain an N-terminal
68-residue BTB/POZ domain (BTB for Bric-a-brac, Tram-
track, Broad-complex; and POZ for Poxvirus and Zinc-
finger), a central a-helical linker region, and a C-terminal
Kelch-repeat domain (Figure 2B).15,16 The Kelch-repeat
domain of KBTBD13 consists of five repeats (Figure S4),
each containing 42 to 49 amino acids, but the overall
homology of the repeats is low. Residues R248, K390, and
R408 are located within the highly evolutionarily
conserved second and fifth Kelch repeats (Figure 2C and
Figure S4), at positions corresponding to b21, b51, and
b53 b sheets of the resolved structure of galactose oxidase,
a model BTB/Kelch protein,15 and are predicted to damage
the corresponding strands of the molecular b-propeller
blades. In light of the pathogenicity of mutations associ-
ated with NEM6, KBTBD13 is likely to have a significant
though as-yet-unknown role in muscle structure and/or
function.
More than 60proteins of the BTB/Kelch family have been
identified,15–19 of which a few are known to be expressed in
skeletal and cardiacmuscle: Krp1 or Sarcosin,18Muskelin,19
andKLHL31.17 BTB/Kelchproteins have been implicated in
a broad variety of biological processes, including cytoskel-
eton modulation, regulation of gene transcription,
ubiquitination, cell migration, and myofibril assembly.
Although the list of known BTB/Kelch proteins is growing,
fewhave been associatedwith humandisease. Gigaxonin is
mutated in patients with giant axonal neuropathy,20
mutations in KLHL7 cause dominant retinal degenera-
tion,21 and KLHL9 mutation is associated with distal
myopathy.22 KLHL9 forms a complex with Cullin 3
(Cul-3)-based ubiquitin ligase through its BTB domain,
and a KLHL9 alteration diminishes its binding to Cul-3.22
Similarly, gigaxonin controls the ubiquitin-mediated
degradation of cytoskeletal proteins, leading to impaired
axonal transport and neuronal death in giant axonal
neuropathy.23 Several other members of the BTB/Kelch
family interact with Cul-3 and participate in direct ubiqui-
tination, demonstrating that members of the BTB/Kelch
protein families define a new class of substrate-specific
adaptors for Cul-3 based ubiquitin ligase.22–25 Whether
this function relates to NEM6 pathogenesis remains to be
determined.
In conclusion, we have identified a member of the BTB/
Kelch family of proteins that if mutated causes muscle
disease characterized by nemaline rod and core formation
and muscle weakness, likely through a mechanism
different than that of nemaline myopathy associated
with mutations in other genes. A combination of gene
mapping, positional cloning, mutation screening, and
high-throughput copy-number analysis was used to iden-
tify the genetic cause of this disease. These findings will
promote understanding of the functional role of the
growing number of BTB/Kelch proteins, specifically
KBTBD13, in skeletal muscle, provide insight into the
pathogenesis of NEM6, and stimulate the development
of treatments for this childhood-onset disease.846 The American Journal of Human Genetics 87, 842–847, DecembSupplemental Data
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found with this article online at http://www.cell.com/AJHG/.Acknowledgments
The authors would like to thank themembers of the affected fami-
lies for their participation in the study.We thank O.Mungunsukh,
USU, for technical advice and for providing RNA from mice
tissues. We are grateful to R. Horowits, NIH, for critical comments
on the manuscript. The authors thank the Biomedical Instrumen-
tation Center of USU for oligo synthesis, DNA sequencing, and
assistance with confocal microscopy. This research was supported
by a USU R080CD grant to N.S. M.O. is supported by FIS grant
PI08-574 from the Instituto Carlos III, Ministry of Education and
Research, Spain. N.G.L. is supported by an Australian National
Health and Medical Research Council (NHMRC) fellowship grant,
403904. K.J.N., G.R., and B.I. are supported by NHMRC project
grant 403941. This work was supported in part by the Intramural
Research Program of the National Institute of Neurological Disor-
ders and Stroke, NIH.
Received: July 19, 2010
Revised: October 9, 2010
Accepted: October 20, 2010
Published online: November 24, 2010Web Resources
The URLs for data presented herein are as follows:
NCBI Build 37.1, http://www.ncbi.nlm.nih.gov/mapview/
NCBI Nucleotide Database, http://www.ncbi.nlm.nih.gov/
nuccore
NCBI Protein Database, http://www.ncbi.nlm.nih.gov/protein
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi.
nlm.nih.gov/Omim/Accession Numbers
The dbSNP accession numbers for the SNPs reported in this paper
are ss262957117, ss262957118, and ss262957119. The NCBI
accession number for the cDNA sequence reported in this paper
is NM_001101362.2.References
1. North, K.N., Laing, N.G., and Wallgren-Pettersson, C.; The
ENMC International Consortium and Nemaline Myopathy.
(1997). Nemaline myopathy: current concepts. J. Med. Genet.
34, 705–713.
2. Ryan, M.M., Schnell, C., Strickland, C.D., Shield, L.K.,
Morgan, G., Iannaccone, S.T., Laing, N.G., Beggs, A.H., and
North, K.N. (2001). Nemaline myopathy: a clinical study of
143 cases. Ann. Neurol. 50, 312–320.
3. Sanoudou, D., and Beggs, A.H. (2001). Clinical and genetic
heterogeneity in nemaline myopathy—a disease of skeletal
muscle thin filaments. Trends Mol. Med. 7, 362–368.
4. Laing, N.G., and Wallgren-Pettersson, C. (2009). 161st ENMC
International Workshop on nemaline myopathy and relateder 10, 2010
disorders, Newcastle upon Tyne, 2008. Neuromuscul Disord.
19, 300–305.
5. North, K. (2008). What’s new in congenital myopathies? Neu-
romuscul. Disord. 18, 433–442.
6. Gommans, I.M., Davis, M., Saar, K., Lammens, M., Mastaglia,
F., Lamont, P., van Duijnhoven, G., ter Laak, H.J., Reis, A.,
Vogels, O.J., et al. (2003). A locus on chromosome 15q for
a dominantly inherited nemaline myopathy with core-like
lesions. Brain 126, 1545–1551.
7. Olive´, M., Goldfarb, L., Lee, H.S., Zagaa, O., Blokhin, A., Gon-
zalez-Mera, L., Moreno, D., Laing, N.G., and Sambuughin, N.
(2010). Nemaline myopathy type 6: Clinical and myopatho-
logical features. Muscle and Nerve, in press.
8. Pauw-Gommans, I.M., Gerrits, K.H., de Haan, A., and van
Engelen, B.G. (2006). Muscle slowness in a family with nema-
line myopathy. Neuromuscul. Disord. 16, 477–480.
9. Monnier, N., Romero, N.B., Lerale, J., Nivoche, Y., Qi, D.,
MacLennan, D.H., Fardeau, M., and Lunardi, J. (2000). An
autosomal dominant congenital myopathy with cores and
rods is associatedwith a neomutation in the RYR1 gene encod-
ing the skeletal muscle ryanodine receptor. Hum. Mol. Genet.
9, 2599–2608.
10. Scacheri, P.C., Hoffman, E.P., Fratkin, J.D., Semino-Mora, C.,
Senchak, A., Davis, M.R., Laing, N.G., Vedanarayanan, V.,
and Subramony, S.H. (2000). A novel ryanodine receptor
gene mutation causing both cores and rods in congenital
myopathy. Neurology 55, 1689–1696.
11. Thierfelder, L., Watkins, H., MacRae, C., Lamas, R., McKenna,
W., Vosberg, H.P., Seidman, J.G., and Seidman, C.E. (1994).
Alpha-tropomyosin and cardiac troponin T mutations cause
familial hypertrophic cardiomyopathy: a disease of the sarco-
mere. Cell 77, 701–712.
12. Olson, T.M., Kishimoto, N.Y., Whitby, F.G., and Michels, V.V.
(2001). Mutations that alter the surface charge of alpha-tropo-
myosin are associated with dilated cardiomyopathy. J. Mol.
Cell. Cardiol. 33, 723–732.
13. Laing, N.G., Wilton, S.D., Akkari, P.A., Dorosz, S., Boundy, K.,
Kneebone, C., Blumbergs, P., White, S., Watkins, H., Love,
D.R., et al. (1995). A mutation in the alpha tropomyosin
gene TPM3 associated with autosomal dominant nemaline
myopathy. Nat. Genet. 9, 75–79.
14. Lu, S., Carroll, S.L., Herrera, A.H., Ozanne, B., and Horo-
wits, R. (2003). New N-RAP-binding partners alpha-actinin,
filamin and Krp1 detected by yeast two-hybrid screening:The Americanimplications for myofibril assembly. J. Cell Sci. 116, 2169–
2178.
15. Prag, S., and Adams, J.C. (2003). Molecular phylogeny of the
kelch-repeat superfamily reveals an expansion of BTB/kelch
proteins in animals. BMC Bioinformatics 4, 42.
16. Stogios, P.J., Downs, G.S., Jauhal, J.J., Nandra, S.K., and Prive´,
G.G. (2005). Sequence and structural analysis of BTB domain
proteins. Genome Biol. 6, R82.
17. Abou-Elhamd, A., Cooper, O., and Mu¨nsterberg, A. (2009).
Klhl31 is associated with skeletal myogenesis and its expres-
sion is regulated by myogenic signals and Myf-5. Mech. Dev.
126, 852–862.
18. Greenberg, C.C., Connelly, P.S., Daniels, M.P., and Horowits,
R. (2008). Krp1 (Sarcosin) promotes lateral fusion of myofibril
assembly intermediates in cultured mouse cardiomyocytes.
Exp. Cell Res. 314, 1177–1191.
19. Prag, S., De Arcangelis, A., Georges-Labouesse, E., and Adams,
J.C. (2007). Regulation of post-translational modifications of
muskelin by protein kinase C. Int. J. Biochem. Cell Biol. 39,
366–378.
20. Bomont, P., Cavalier, L., Blondeau, F., Ben Hamida, C., Belal,
S., Tazir, M., Demir, E., Topaloglu, H., Korinthenberg, R.,
Tu¨ysu¨z, B., et al. (2000). The gene encoding gigaxonin,
a new member of the cytoskeletal BTB/kelch repeat family, is
mutated in giant axonal neuropathy. Nat. Genet. 26, 370–374.
21. Friedman, J.S., Ray, J.W., Waseem, N., Johnson, K., Brooks,
M.J., Hugosson, T., Breuer, D., Branham, K.E., Krauth, D.S.,
Bowne, S.J., et al. (2009). Mutations in a BTB-Kelch protein,
KLHL7, cause autosomal-dominant retinitis pigmentosa.
Am. J. Hum. Genet. 84, 792–800.
22. Cirak, S., von Deimling, F., Sachdev, S., Errington, W.J., Herr-
mann, R., Bo¨nnemann, C., Brockmann, K., Hinderlich, S.,
Lindner, T.H., Steinbrecher, A., et al. (2010). Kelch-like homo-
logue 9 mutation is associated with an early onset autosomal
dominant distal myopathy. Brain 133, 2123–2135.
23. Allen, E., Ding, J.,Wang,W., Pramanik, S., Chou, J., Yau, V., and
Yang, Y. (2005). Gigaxonin-controlled degradation of MAP1B
light chain is critical toneuronal survival.Nature 438, 224–228.
24. Furukawa, M., He, Y.J., Borchers, C., and Xiong, Y. (2003).
Targeting of protein ubiquitination by BTB-Cullin 3-Roc1
ubiquitin ligases. Nat. Cell Biol. 5, 1001–1007.
25. Pintard, L., Willems, A., and Peter, M. (2004). Cullin-based
ubiquitin ligases: Cul3-BTB complexes join the family.
EMBO J. 23, 1681–1687.Journal of Human Genetics 87, 842–847, December 10, 2010 847
